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Screening for cervical, prostate, and breast cancer: Interpreting the
evidence
Abstract

Cancer screening is an important component of prevention and early detection in public health and clinical
medicine. The evidence for cancer screening, however, is often contentious. A description and explanation of
disagreements over the evidence for cervical, breast, and prostate screening may assist physicians,
policymakers, and citizens faced with screening decisions and suggest directions for future screening research.
There are particular issues to be aware of in the evidence base for each form of screening, which are
summarized in this paper. Five tensions explain existing conflicts over the evidence: (1) data from differing
contexts may not be comparable; (2) screening technologies affect evidence quality, and thus evidence must
evolve with changing technologies; (3) the quality of evidence of benefit varies, and the implications are
contested; (4) evidence about harm is relatively new, there are gaps in that evidence, and there is
disagreement over what it means; and (5) evidence about outcomes is often poorly communicated. The
following principles will assist people to evaluate and use the evidence: (1) attend closely to transferability;
(2) consider the influence of technologies on the evidence base; (3) query the design of meta-analyses; (4)
ensure harms are defined and measured; and (5) improve risk communication practices. More fundamentally,
there is a need to question the purpose of cancer screening and the values that inform that purpose,
recognizing that different stakeholders may value different things. If implemented, these strategies will
improve the production and interpretation of the methodologically challenging and always-growing evidence
for and against cancer screening.
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Screening for cervical, prostate and breast cancer:
interpreting the evidence
Stacy M Carter, Jane Williams, Lisa Parker, Kristen Pickles, Gemma Jacklyn, Lucie Rychetnik,
Alexandra Barratt (2015)

Cancer screening is well-established in high income countries, but its evidence base is
constantly evolving and often contentious. This leaves physicians and policymakers in a
difficult position, forced to act in the context of methodological complexity and substantive
disagreement.1,2 Three cases of screening for cancer or cancer risk are considered: cervical,
prostate and breast screening. The unique characteristics of the disease, test and program
in each case are outlined in Table 1. Tables 2-4, catalogue sources of controversy in each
case; these are discussed in more depth below. The concluding section presents five
common themes that may help explain the ongoing controversies.
The aim is not to synthesize the evidence, but to provide the ‘backroom’ story of the
evidence on cancer screening, and so illuminate why experts so often disagree.

Cervical screening
Cervical screening is one of the best-supported and least controversial forms of cancer
screening. Nonetheless, there are potentially contentious features of the cervical screening
evidence base. These are:
1) Dependence on observational data;
2) Understanding, communicating and managing the balance of benefit and harm; and
3) The uncertain future impact of new technologies.
The first challenge in the cervical screening evidence base is the status of the existing
evidence. Screening was established in parts of Europe and North America between the late
1940s and early 1960s and data from those programs, rather than from controlled trials,
provide the evidence base for cervical screening effectiveness. Observational studies
compared screened and unscreened populations and showed reduced cervical cancer
incidence and mortality in the former.3-5 This evidence base clearly shows that cervical
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screening reduces morbidity and mortality: what is less clear is who to screen, when, and
how to optimize benefit and minimize harm.
The cervical screening evidence base is susceptible to the well-known biases of any
observational study.1 It is not clear how these likely biases should be taken into account. In
addition, the observational data about cervical screening crosses jurisdictions in which there
are substantially different programs and reporting standards. This means that these
observational data from different settings may not be as easily comparable as is often
assumed (Table 1). To minimize bias, meta-analysis of Randomized Controlled Trial (RCT)
evidence is the preferred method for estimating benefit and harm in screening. RCT
evidence of different screening technologies, and combinations of technologies, is
emerging. This may add more certainty to the cervical screening evidence base, although
some of the findings from RCTs in low and middle income countries (LMICs) may not be
transferable to other settings.6-9
Table 1: Disease, test and program characteristics in each case
Cervical cancer
Pap smear using
conventional &/or liquid
based cytology +/computer-assisted reading.
HPV DNA testing increasing
+/- cytology. Visual
inspection with acetic
acid/liquid iodine (VIA/VILI)
in LMICs.
Pap test developed late
1930s.

Prostate cancer
PSA test.
New testing methods,
including use of
biomarkers, are being
developed. DRE also used.

Breast cancer
Mammogram. Fixed or
mobile mammogram unit;
recently widely upgraded to
digital technology.

First commercial PSA test
released in 1986.

When test was first
used for screening

Used to screen
asymptomatic women
from the 1940s.

USFDA approved PSA test
for prostate cancer
screening in 1994.

What test is
designed to detect

Abnormal cells on the
cervix (cytology, VIA/VILI)
OR Presence of oncogenic
HPV strains (HPV test).
HPV-caused lesions are
potential precursors for
cervical cancer.

Raised serum PSA levels.

X-ray used for breast
st
disease 1910s; 1 screening
RCT 1963-75.
Ad hoc screening from mid
th
60
20 century; population
screening programs 1980s
onwards (based on
publication of results from
early RCTs).
Variations in soft tissue
radiolucency. Originally
diagnostic.

Tests used

When test was
invented

Relationship
between test and
target disease?
What results of
screening are
reported
Contention over
test itself

Lesions: nature & severity
(grade) of changes.
Reporting standards differ.
HPV reported by type.
Cytology is prone to human
error. Terminology &
reporting standards vary.
Sensitivity & specificity
61
estimates vary widely.

Poor. Test not developed
to screen for cancer.
Elevated PSA may not
indicate cancer risk.
Prostate Specific Antigen
levels, expressed as
nanograms of PSA per
millilitre (ng/ml) of blood.
There is no meaningful
‘normal range’ for the PSA
test in screening.

Cancers have characteristic
(often subtle) soft tissue
appearances on x-ray.
Apparent presence of
masses and lesions
suspicious for invasive
and/or in situ cancer.
There is variation in what
degree of suspicion
constitutes a positive
screen.
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Variations between
jurisdictions that
may change the
evidence base
regarding benefit
and/or harm

IARC recommends 3-yrly
cytology screening from
25yrs. Evidence base pools
data from widely varied
5
programs: start-age
ranges from 18-30yrs,
interval 1-5yrs; reporting
standards, terminology &
treatment vary.

Developments in
the test

Tests that detect
oncogenic-type HPV may
supersede cytology as
primary screening test.

Differences in target age,
recommended finishing
ages, screening intervals,
thresholds definition of
“abnormal”, biopsy
thresholds.

Differences in target age,
screening intervals,
thresholds for recall &
biopsy.
Service studies may differ
in: participant population
age (and therefore
underlying cancer risk),
follow-up, out-of-study
screening.
Increasing use of
tomosynthesis (integrated
2/3D mammography) and
MRI which may contribute
to both benefits and harms.

New test rules in
development. Variations
proposed (free: total PSA
ratio, PSA density, velocity,
doubling time, prostate
health index) for clinical
significance. No evidence
these improve health
2
outcomes .
Table Legend: DRE Digital Rectal Examination; HPV Human Papillomavirus; IARC International Agency for
Research on Cancer; LMICs Low and Middle Income Countries; MRI Medical Resonance Imaging; PSA Prostate
Specific Antigen; RCT Randomized Controlled Trial; USFDA US Food and Drug Administration; VIA visual
inspection of the cervix using acetic acid to highlight precancerous lesions; VILI visual inspection of the cervix
using Lugol’s iodine to highlight precancerous lesions.

The second challenge in this evidence base concerns understanding, communicating and
managing the balance of benefit and harm: this problem has several dimensions. It is easy to
inadvertently overstate the mortality benefit of cervical screening, particularly in highincome countries. This is because mortality from cervical cancer in high-income countries is
considerably lower than for cancers such as breast and prostate. This was true even prior to
widespread Pap-smear testing. For example the age-standardized mortality rate from
cervical cancer in the UK was approximately 8/100,000 in 1971, compared to 37.5/100,000
for breast cancer and 20/100,000 for prostate cancer.10 Thus, even substantial proportional
(or relative risk) reductions in mortality attributed to screening may represent only small
reductions in the absolute number of deaths prevented in well-resourced countries (Table
2). Cervical cancer, however, remains a significant burden and leading cause of cancer
mortality in some low-income regions.11
Table 2: Main issues in cervical cancer screening
Issue
Incidence and mortality of
cervical cancer is low in
high income countries
Cervical screening reduces
morbidity and mortality
from cervical cancer.
There is no RCT evidence
from high income countries
RCTs are being conducted in
LMICs
It is easy to overstate the
benefits of cervical cancer
screening because the

Explanation
The incidence of cervical cancer is much lower than e.g. breast or prostate
cancer, so number needed to screen over many years to avoid one death is
12
high.
Early Nordic observational studies suggest a mortality benefit from screening
using the Pap test.
5
Organised programs confer greater benefit than opportunistic screening.
Because Pap test screening for cervical cancer was introduced so early, it was
not possible or ethical to conduct an RCT of its effectiveness.
These will be a useful evidence base for LMICs.
Because incidence is low, number needed to screen is high and absolute risk
reduction low.
Statements of benefit may obscure the relatively small absolute number of
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underlying mortality rate is
low

people affected. For example mortality is often said to have halved in the
decade following commencement of organised screening in Australia: this is
accurate, but the absolute change was from only 4/100,000 to 2/100,000
women.
Most cervical lesions
It has been recognised since the 1970s that most cervical lesions will not
regress
progress to cervical cancer.
It is not clear what
It may never become clear which lesions will regress or what proportion of
proportion of lesions
them will regress.
62
12
63
regress, or which lesions
CIN3 progression to cancer has been estimated at 12%, 20% and 30% in
will regress
different studies.
Overtreatment is difficult to The majority of treatment is overtreatment, but as it is not possible to identify
measure and to manage
which lesions will regress this may not be resolvable with the technology
currently available.
There are vastly more abnormal results than there are invasive cancers,
especially in women <25. E.g. in Australia in 2010 the incidence of invasive
cancer in women <25 was 1.5/100,000, but 40,000 out of the 250,000 screens
64
in women <25 returned an abnormal result.
15
Perinatal morbidity in treated women is the main iatrogenic harm of concern.
The evidence base is
Evidence about cervical screening comes mostly from monitoring data from
affected by differences in
screening programs. However, different countries run their programs
program design between
differently. They use different tests, screening ages and screening intervals.
countries
They classify and report on their programs using different terminology and
standards. Then the data from these very different contexts are combined. This
has implications for the evidence base.
Screening technology is
Due to HPV vaccination a move away from cytology seems likely; an alternative
changing
future might be mass HPV screening with cytological examination of those with
positive HPV tests.
It is unclear what the incremental benefits and costs of these new technologies
over existing screening programs will be. This is a rapidly evolving part of the
evidence base in cervical screening.
Table legend: CIN3 Cervical intra-epithelial neoplasia; HPV Human Papilloma Virus; LMICs Low and Middle
Income Countries; RCT Randomized Controlled Trial.

In addition, the treatments triggered by screening may be unnecessary and harmful in some
cases. Cervical screening reduces cancer incidence as well as mortality. This is because it
detects cellular abnormalities on the cervix, or pre-cancerous lesions, caused by human
papillomavirus (HPV—Table 1). Cervical cancer is a rare outcome of persistent infection over
a long time. However cellular abnormalities are common: there is an estimated lifetime
incidence of 40% in women born since 1960.12 Also, progression appears to be less linear
than originally thought,13 and most HPV infections regress spontaneously. This means 4/5
women with dysplasia may be treated unnecessarily;12 but at present it is not possible to
identify which individual high-grade lesions will regress (and so can be left untreated) or will
progress (so require treatment–Table 2).
The evidence does suggest a solution however: to focus on minimizing harm, particularly in
women under age 25. The evidence shows that: a) HPV infection is most likely to
spontaneously regress in this group; b) paradoxically, these women also experience more
abnormal cytology, treatment, and cervical incompetence and perinatal morbidity as a
result of treatment; and crucially c) there is no mortality benefit in screening this age
group.14, 15 As a result, many countries are delaying commencement of screening until the
age of 25 (Table 1) and/or recommending screening thereafter only every 3-5 years.16, 17
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Although this change is supported by the evidence, in many jurisdictions women continue to
be screened earlier and more often than these guidelines would support. 5, 18, 19
Finally, it is important to anticipate the future impact of new technologies on the evidence
base and on practice.20, 21 Research increasingly supports screening women aged ≥30 using
an oncogenic-type HPV test instead of or in addition to cytology.6 The US Preventive
Services Taskforce (USPSTF), for example, now recommends that women aged 30 to 65
years can screen with a combination of cytology and HPV testing every 5 years if they wish,
rather than with cytology alone every 3 years.7 The FDA has recently approved the use of
HPV testing alone as a primary screening test,22 which seems likely to result in further
revision of recommendations. The recommendations are somewhat ahead of the evidence –
with the exception of an Indian cluster RCT,8 primary HPV testing has not yet shown
mortality benefit. Similarly, comparative benefits and harms of different sequential
combinations of HPV and cytology testing are not yet clear. However RCTs of newer
screening technologies (e.g. HPV tests, including self-testing and testing in vaccinated
populations, and computer assisted cytology reading) are underway. HPV vaccination will
further reduce underlying risk in the population and so potentially reduce the relevance of
the existing evidence on cervical screening.

Screening for prostate cancer
Unlike cervical screening, prostate specific antigen (PSA) testing for prostate cancer risk is
intensely contested;23 this includes contention over the relationship between evidence and
practice. Important issues include:
1) There is inconsistency between the findings of different trials (and tension over the
interpretation of observational findings);
2) Tests and thresholds for abnormality vary within and between studies; and
3) The evidence suggests that the PSA test performs poorly for screening purposes.
The first challenge is the quality and interpretation of research about the efficacy and
effectiveness of PSA testing. Observational data from highly-screened communities is
sometimes used to argue that testing reduces prostate cancer mortality.24-26 However, as
noted earlier, findings from observational studies may be misleading because of
characteristic biases such as lead time, length time, and selection bias.2, 27 Early RCTs were
of poor quality (Table 3).2, 27 Since then, two ongoing RCTs have reported results: the
European Randomized Study of Screening for Prostate Cancer (ERSPC), and the USA Prostate
Lung Colorectal and Ovarian Cancer (PLCO) trial. PLCO has shown no effect on prostate
cancer-specific or all-cause mortality.28 ERSPC reported reduced prostate cancer mortality in
screened men but no change in all-cause mortality.29 There is considerable controversy over
trial design (Table 3). Although difficult to quantify, frequency of testing and follow-up, and
type of treatment provided after diagnosis, are likely to affect outcomes reported from
trials.30-32
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Table 3 Main issues in prostate cancer screening
Issue
Most prostate cancer is not
life threatening
Early trials of PSA screening
were of poor quality
Large RCTs are currently
underway
There is controversy over
the design of the current
large RCTs

PSA screening may
decrease prostate cancer
death
PSA screening is unlikely to
decrease all-cause mortality
The PSA test is not prostate
cancer-specific

PSA test manufacturers and
PSA thresholds vary
between studies,
laboratories, and clinicians

Explanation
Although prostate cancer can be life threatening, the vast majority of cases are
indolent.
Early trials—which reported very positive findings—had serious
methodological problems, including low participation in screening, failure to
randomise, and failure to analyse by intention to screen.
ERSPC trial, and the USA PLCO trial have made interim reports but are ongoing.
These are the only large, methodologically sound trials of PSA screening
conducted to date.
ERSPC included different countries using different screening tests and
procedures. Those screened in the trial were more likely to be treated in a
University hospital. The Swedish subset of ERSPC compared volunteer
screenees (probably a healthier group) to whole-population controls
(particularly significant because Sweden was one of only two, out of seven,
subgroups to report statistically significant reductions in prostate cancer
mortality after 11 years. These patterns likely to bias results in favour of
screening.
In PLCO, >50% of controls were screened during the trial, 44% of participants
had previously been screened.
Methodologists disagree on whether these biases are fatal to the results of the
trials.
Some trials suggest reductions in incidence of prostate cancer death.
Observational studies in highly-screened populations suggest lower prostate
cancer mortality.
Only ERSPC has reported a mortality benefit, which was very small in absolute
terms. 1055 men would have to be screened to prevent one death from
30
prostate cancer over 11 years.
PSA test has poor sensitivity and specificity for detecting prostate cancer. A
PSA >4.0ng/ml produces a 6.2% false positive rate but detects only 20.5% of
65
cancer cases.
PSA test cannot distinguish increased cancer risk from other common
conditions e.g. benign prostatic hyperplasia, prostatitis.
Certain medications (e.g. finasteride), ejaculation, and prostate manipulation
can also increase PSA levels.
Studies and laboratories employ more than one kind of PSA test and different
abnormal thresholds.
The evidence base is thus hard to interpret due to lack of comparability.
Conventional threshold for further investigation is 4ng/mL, but men with PSA
66
levels 4-10ng/ml may not have prostate cancer, and men with results
25, 67
<4ng/mL can show histological evidence of prostate cancer.
Lowering the threshold below 4ng/mL would increase overdiagnosis and
27, 68
overtreatment of clinically unimportant disease.
A meaningful threshold for screening may not exist because of the test’s poor
sensitivity and specificity i.e. the PSA test has little utility as a screening tool for
prostate cancer. There is currently no alternative test available.
In the USA, for example, up to 90% of men with prostate cancer diagnosed as a
56
result of PSA testing receive treatment.

PSA screening can increase
the likelihood of receiving
treatment
Prostate cancer treatment
Treatment can result in erectile dysfunction or impotence, anxiety, urinary
can produce considerable
incontinence, bowel dysfunction, or death.
negative consequences
Table Legend: ERSPC European Randomized Study of Screening for Prostate Cancer; PLCO Prostate Lung
Colorectal and Ovarian Cancer trial; PSA Prostate Specific Antigen.
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Expert bodies increasingly advise against PSA screening. The USPSTF concluded that the
mortality benefit is very small and outweighed by risk of harm.33 The American College of
Preventive Medicine has similarly concluded that populations should not be routinely
screened with the PSA test, due to insufficient evidence.34 The Australian National Health
and Medical Research Council evidence guideline on PSA testing in asymptomatic men has
recently concluded that there is no effect of PSA testing on all-cause mortality, and that no
conclusions can be drawn about prostate cancer mortality.35 These decisions are consistent
with the evidence, which suggests that PSA testing may reduce the short term risk of dying
from prostate cancer by a very small amount, at the cost of a much greater risk of harm,
including from false positive results, overdiagnosis and overtreatment. The question this
raises is: if a screened man will not die any later than an unscreened man, is it meaningful to
prevent him from dying of prostate cancer in particular? And at what cost (harms to the
man as well as expense to the man and the health system) should this goal be pursued? This
question seems to divide experts, not least according to whether they care for men with the
disease or have experienced it themselves.
The second problem in the PSA testing evidence is interpretability and comparability of PSA
results. This is an issue for many screening tests (see Table 1), but especially for the PSA
test. Manufacturers and laboratories employ divergent PSA calibrations, producing different
PSA readings from the same sample.36 Even when identical methods are used, thresholds
set to separate ‘normal’ from ‘high risk’ PSA levels often differ. Within and between studies
different standards are often combined, potentially invalidating conclusions.25, 37 Tests and
thresholds used by different countries participating in large trials often vary (Table 3), and
trial study groups have been unable to identify acceptable PSA cut-off points for prostate
cancer screening. This makes it difficult to compare study results and apply them to real-life
settings.
The final problem with interpreting the evidence about PSA testing is addressing the
potential for harm. The evidence suggests that sensitivity and specificity of the test are poor
(Tables 1 & 3), which means cancers are missed (poor sensitivity) and false positives are
common (poor specificity). The evidence suggests that PSA testing increases diagnosis of
indolent disease, frequently cascades to diagnostic biopsies and follow-up treatments, and
produces physical and psychological harms and costs: for every life saved by the PSA test, up
to 48 men may be overtreated (Table 3).38 Determining whether this is acceptable requires
difficult debate over the nature of a good outcome, and what harm or expense that
outcome might justify.

Screening for breast cancer
Like the evidence for PSA testing, the evidence for breast screening has been controversial.
Important features of this evidence base include:
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1) Uncertainty regarding the extent of breast cancer mortality reduction benefit;
2) Uncertainty regarding the extent of harm; and
3) Disagreement about managing in situ disease.
The first challenge for the evidence on breast screening is that despite a considerable body
of research, the degree to which breast screening reduces breast cancer mortality remains
unclear. The evidence base includes 11 RCTs (1971-2006), numerous observational studies,
and mathematical models. It is probable that an invitational program of breast screening by
mammography offers a population breast cancer mortality benefit, particularly for women
aged 50-70. If poorer-quality RCTs are removed from meta-analyses this benefit is reduced.
By how much is unclear (Table 4). Absolute and relative benefits are lower in women aged
<50.39 Also, treatment has greatly improved in recent decades, so including RCTs from the
1970s–1990s may overstate the benefit of screening (Table 4).1, 40-44 The degree to which
widely-observed declines in breast cancer mortality are attributable to improvements in
treatment remains contested.45 It is unclear how this can be resolved. Incremental changes
in technology—from film mammography to digital mammography, tomosynthesis
(integrated 2/3D mammography) and MRI to screen high risk women—may also affect the
balance of screening benefits and harms.46, 47
Table 4 Main issues in breast cancer screening
Issue
Mortality
benefit exists
The extent of
mortality benefit
is contentious

Mortality
benefit is less
than originally
thought
The harm from
false positive
screening tests
varies between
programs and
populations

The extent of
overdiagnosis is
contentious

Explanation
Most studies show mortality benefit from organised mammographic screening, especially
40-43
for women aged 50-70, of approximately 20%.
Estimates of benefit vary considerably.
Different study types are used including RCTs, observational studies and modelling.
Meta-analysis of RCTs is widely regarded as the best way to identify population benefits,
but different meta-analyses include or exclude different RCTs due to differing judgements
40-43
about study quality.
Recent meta-analyses of RCTs suggest that benefit is lower than suggested by the earliest
studies.
This can be partly attributed to problems in quality with some of the RCTs.
It has been hypothesised that treatment improvements in recent decades may leave less
40-43
room for screening to have an effect and make older trial data less relevant.
The rate of false positives varies as a result of factors such as:
 Test factors e.g. equipment quality; skill of the clinicians reading the mammograms.
 Differing policies and standards regarding acceptable levels of false positives and false
negatives.
 Frequency of screening in the program (increased frequency tends to increase the
absolute number of false positives).
 Individual participant factors (e.g. greater breast density in some women, including
pre-menopausal women and women taking hormone replacement therapy (HRT))
which can make mammogram interpretation more challenging (and false positives
more common).
 Population factors: the frequency of false positives in part depends on the positive
predictive value of the test, which depends on the prevalence of disease in the
screened population. This depends on population risk profile (e.g. younger women
48
have lower incidence).
Estimates of overdiagnosis vary as a result of factors including the population studied,
research questions asked (e.g. total cancer or invasive cancer only), methods used (e.g.
comparing incidence in intervention and control arms of RCTs, comparing observational
annual incidence data, comparing observational cumulative incidence data, using
10 | P a g e

simulated population models), correction for possible biases such as lead time, and
1, 15, 44, 50
fundamental assumptions when estimating overdiagnosis in models.
Biological
Before the onset of screening, in situ disease was mostly diagnosed in conjunction with an
consequences of invasive cancer. It was not anticipated to be a common isolated finding on screening.
in situ disease is
It is unclear what the right response to increased diagnosis of in situ disease should be.
unclear
Knowledge of the natural history of in situ breast diseases is improving but still
incomplete.
Diagnosis and management are controversial, especially for less aggressive diseases (e.g.
low grade DCIS) where risk of death is only slightly increased but surgery to negate the risk
40-43
may be extensive.
There are small
Harms from radiation during mammography are generally agreed to be real, and may be
radiation harms
greater in women screened more often (e.g. those identified as carrying potentially
69, 70
of screening
harmful mutations in the BRCA1 or BRCA2 genes).
However in screening of the general
population, these risks are extremely small, and likely to be further reduced by the
implementation of digital mammography.
BRCA1/BRCA2 BReast CAncer susceptibility gene 1 and 2; DCIS Ductal Carcinoma In Situ; RCT Randomised
Controlled Trial.

The second concern is the extent of harm caused. Invitational mammography programs
cause harm, including from false positives and overdiagnosis. The absolute rate of false
positives can vary according to equipment used, skill and experience of film readers, test
thresholds and screening frequency (Table 4).48 Although the rate of false positives per
screen may be low, they accumulate, so the chance of false positive recall or biopsy over a
lifetime is much higher. Increasingly, evidence suggests that breast screening produces
overdiagnosis of both invasive and in situ breast cancer. Although experts agree that
mammography screening causes overdiagnosis, there is disagreement on its extent. A
recent meta-analysis suggests that, in women invited to screening, there is an 11% lifetime
risk of overdiagnosis as a proportion of cancers diagnosed, and a 19% risk during the active
screening period.40, 43 Harms, especially overdiagnosis, may tend to outweigh benefits in
women >70 as they age.49 However the relevant evidence is highly contentious for
methodological and other reasons explained in Table 4.44, 50
The final challenge in this evidence base concerns ductal carcinoma in situ (DCIS), which
represents approximately 17% to 34% of screen-detected cases and 20%–25% of all newly
diagnosed cases of breast cancer in the USA.51 Women are rarely diagnosed with DCIS
because they experience symptoms: DCIS is diagnosed almost entirely as a result of
screening. Overdiagnosis of DCIS is considered by many an important harm of
mammographic screening. However the evidence is not clear on either the natural history of
DCIS or how aggressively DCIS should be treated. More research is needed to evaluate
treatments for in situ disease.40, 44

What characteristics of the screening evidence base could explain expert disagreement?
In high-income countries, cancer screening is a familiar feature of preventive medical care.
Screening is expected—with good reason—to be informed by evidence. Across these three
cases, there are two less-often discussed tensions and three more explicit tensions that help
to explain why interpreting the evidence is such a difficult task.
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Tensions in the evidence base that are less-often discussed
Two tensions in the evidence base are under-examined: the comparability of data between
studies and contexts, and the impact of technological developments. These tensions are
also difficult to resolve and potentially destabilizing.

Data from very different contexts may not be comparable
Data from different contexts may not be comparable, particularly for observational data
from monitoring studies. As shown, the evidence base contains data from different times,
countries and programs, and from populations with varying event rates (Table 1).
Transferability of this evidence is difficult for several reasons. Because screening trials are
particularly large and need long follow-up to show effects, they can be especially susceptible
to the passage of time. When early trials were conducted, screening techniques were less
developed, treatments less effective, cancer incidence lower and cancer mortality often
higher. (Breast screening evidence, for example, includes decades-old trials: treatment has
progressed substantially since they were conducted.) Evidence from screening trials is also
susceptible to local variation (e.g. in disease biology, event rates and age distribution), not
least because screening is applied to whole populations, not just people who are ill. (As HPV
vaccination is implemented differently around the world, for example, the underlying event
rate for cervical cancer will change dramatically.) The resource intensiveness of cancer
screening trials also means that: 1) few trials are done (leaving less evidence to interpret); 2)
trials are often funded by industry (changing the research questions asked); and 3) trials are
somewhat dependent on local screening and treatment practices (e.g. target age, screening
intervals, testing techniques, follow-up time, available treatment). The variability and
transferability of screening evidence is a challenge for methodologists; even more so for
clinicians and policymakers, as the characteristics on which the evidence depends are not
always made clear in reporting.

Screening technologies affect evidence quality, evidence must evolve with changing
technologies
Cancer screening relies on complex cascades of technology for collecting, imaging, analysing
and interpreting possible changes in human bodies. Without the technology, there is no
screening, but as technology evolves, it potentially makes existing evidence obsolete. 52
The evidence on PSA is hampered by poor technology. The PSA test has limited sensitivity
and specificity, studies and laboratories use multiple test types and different thresholds,
there is no meaningful ‘normal range’, and new test rules do not appear to change patient
outcomes. Some propose using test results only within, rather than between, patients, but
the poor test characteristics of PSA make even this problematic. It is understandable that
clinicians want to retain some tool to measure prostate cancer risk.53 But given the test
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characteristics of the PSA, it may not be possible to generate a meaningful evidence base
about its use in populations.
The cervical screening evidence base is shifting because of changing technology; tests that
detect oncogenic-type HPV may become the primary form of screening in vaccinated
populations. Mammography remained relatively constant in the 20th Century, changing only
incrementally from film to digital mammography. In the 21st Century we face substantial
technological change, with moves to tomosynthesis (integrated 2/3D mammography) and
MRI screening of high risk women. Although tomosynthesis is receiving considerable
attention in the lay press and peer reviewed literature, attempts to estimate its effects have
been based on opaque assumptions and limited evidence. It seems possible that both MRI
and tomosynthesis will enhance both the benefits and harms of screening, but at present
this is unknown.46, 47
Acknowledged tensions in the evidence base
Three other, more explicit, tensions are over the quality of evidence of benefit, the
relatively new evidence regarding screening harms, and risk communication.

The quality of evidence of benefit varies, and the implications are contested
When one expert says to another ‘you are wrong about the evidence on screening’, she is
likely to mean this: ‘I disagree with the criteria that you have used to separate good-quality
studies, which should be included, from poor-quality studies, which should be excluded. I
therefore disagree with your conclusion.’
The cancer screening evidence base contains observational studies, RCTs, and modelling, of
widely varying quality, and with disparate results. Early studies of screening generally
suggested greater benefit, and later studies less benefit, which may be because early trials
were poorly designed (e.g. PSA) or because recent treatment improvements leave less room
for screening to provide benefit (e.g. breast screening). Even new trials contain
methodological flaws (e.g. PLCO, ERSPC), and methodologists often disagree about study
design, particularly over whether screened and unscreened groups are comparable.
New RCTs are expensive and logistically challenging, so are rare. Thus new conclusions
generally arise from reanalyses of existing research findings rather than from new trials.
Researchers performing meta-analyses must decide on criteria for including and excluding
studies. The recent Marmot review of the evidence on breast screening demonstrates that
this is possible,40 even in high-profile situations, but disagreement over criteria is likely to
remain. And when new analyses produce new findings, those whose settled beliefs are
challenged may perceive the chosen criteria as arbitrary or incorrect. This highlights the
importance of transparency regarding how and why meta-analyses are conducted.
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Evidence about harms is relatively new, there are gaps in that evidence, and disagreement
about what it means
Initially, cancer screening researchers focused on measuring screening benefits; they have
only recently turned to potential harms. For all three cases—cervical, prostate and breast
cancer (including DCIS)—there is limited evidence about which instances of disease or predisease are aggressive, so require treatment, and which will be indolent or regress. Because
of this, many people will be over-treated, and may be harmed. Researchers are trying to
address this gap, by studying the mortality benefit of treatment for small, grade 1, node
negative breast cancers, for example, or the genetic profile of aggressive versus indolent
prostate cancers. This work may assist in future. In the meantime, existing knowledge
suggests opportunities to reduce harm. For example, there is currently no way to determine
which cervical lesions will regress or progress. However epidemiological data demonstrates
that women 18-25 are most likely to have unnecessary treatment, experience harms from
treatment, and fail to benefit from treatment. This has led some jurisdictions to restrict
cervical screening to women aged over 25.
Even when evidence about screening harms emerges, experts often disagree about what it
means and how to respond. This may be in part because public health and medical
professionals have learned to think in a particular way, and have taught citizens to think
similarly, of cancer and pre-cancer as progressive and life-threatening, and screening as one
of few defences against this threat. For the first several decades of screening research,
harms were rarely measured. Although later research suggested that screening may harm, it
may be difficult for this evidence to reach public attention given the powerful cultural
meaning of cancer death.54, 55 New facts about screening harms are hotly contested, with
regard both to their accuracy and their implications. And screening programs continue to be
evaluated primarily against increasing participation targets, rather on the likely balance
between benefit and harm achieved.
For example, it is generally accepted that prostate biopsies and prostate cancer treatments
are likely to produce harms. This is taken as a fact, but that fact is interpreted very
differently. Some argue that most screen-detected prostate cancers are indolent, so most
diagnosis is overdiagnosis, and most harm done is unnecessary harm. They conclude that
insurers or policymakers should constrain clinicians who test healthy men, thus preventing
harm. Others take a different view, that without PSA testing clinicians have no way of
diagnosing tumours that would develop or metastasize. These experts tend to take the view
that insurers or policymakers should leave testing open to clinicians, and allow the
possibility of harm to be dealt with via more judicious decisions about treatment. Their
opponents might counter with studies showing that men diagnosed with prostate cancer
generally proceed to treatment rather than ‘watching and waiting’.56 Although each party
can present data of some kind to support their claims, it is worth remembering that data
become evidence only through interpretation, and that experts are susceptible to biases in
this interpretive process.57, 58
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Evidence about outcomes is often poorly communicated, despite the evidence about
communication
Researchers and programs tend to express outcomes using relative risks, which incorporate
baseline risk and so are easier to generalize across contexts. However research shows that
relative risks encourage lay people and clinicians to overemphasize benefits and minimize
harms. This has been acknowledged as ethically problematic, potentially biasing or
manipulating people’s perceptions, misleading them, and undermining their autonomy.59 If
experts are obliged to communicate honestly with citizens—an obligation that seems
supportable—this becomes an urgent issue to address for all forms of cancer screening.

Conclusions
The benefits and harms of screening are often finely balanced; more than anticipated when
screening was established. There are both unique and shared characteristics of cervical,
prostate and breast screening that help to explain the challenge of balancing benefit and
harm. These include the incomparability of data from different times, places and programs,
the instability of the very technology on which screening is based, disagreement on which
studies are well-enough designed to be taken seriously, gaps in knowledge, and
disagreement about how to understand newly emerging evidence of harm. This suggests
five principles for evaluating and using the evidence:
1)
2)
3)
4)
5)

attend closely to transferability;
consider the influence of technologies on the evidence base;
query the design of meta-analyses;
ensure harms are defined and measured; and
improve risk communication practices.

However even more fundamental are questions about the purpose of screening, and who
should make decisions about screening. Should insurers or policymakers leave screening
options open for clinicians and patients to choose? Or should they be directive, promoting
some forms of screening and limiting others to minimize harm? Should community
engagement and deliberation guide screening policy and practice? And what should the
purpose of screening be? There are many potential aims of cancer screening, including
preventing cancer death, reducing all-cause mortality, minimizing anxiety, maximizing cost
efficiency and/or minimizing avoidable harm. These different aims reflect different values,
values that may differ between patients, clinicians, funders and policymakers. Questions
about the evidence base need resolution. This should be complemented with clear thinking
about the aims of screening. Only when the aims of screening are clear will researchers be
able to generate an evidence base sufficient to assist decision-making, and clinicians be able
to best support their patients to make good screening decisions.
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